Specifically, participants with the SLC6A2 GG genotype exhibited a clear linear improvement in ADHD symptoms as the dose increased, suggesting a dose-dependent therapeutic effect. This evidence concerns the gene SLC6A2 and attention deficit-hyperactivity disorder.